-
- Jason F. Wiggins
- Authors' Affiliation: Mirna Therapeutics, Inc., Austin, Texas
-
- Lynnsie Ruffino
- Authors' Affiliation: Mirna Therapeutics, Inc., Austin, Texas
-
- Kevin Kelnar
- Authors' Affiliation: Mirna Therapeutics, Inc., Austin, Texas
-
- Michael Omotola
- Authors' Affiliation: Mirna Therapeutics, Inc., Austin, Texas
-
- Lubna Patrawala
- Authors' Affiliation: Mirna Therapeutics, Inc., Austin, Texas
-
- David Brown
- Authors' Affiliation: Mirna Therapeutics, Inc., Austin, Texas
-
- Andreas G. Bader
- Authors' Affiliation: Mirna Therapeutics, Inc., Austin, Texas
説明
<jats:title>Abstract</jats:title> <jats:p>Tumor suppressor microRNAs (miRNA) provide a new opportunity to treat cancer. This approach, “miRNA replacement therapy,” is based on the concept that the reintroduction of miRNAs depleted in cancer cells reactivates cellular pathways that drive a therapeutic response. Here, we describe the development of a therapeutic formulation using chemically synthesized miR-34a and a lipid-based delivery vehicle that blocks tumor growth in mouse models of non–small-cell lung cancer. This formulation is effective when administered locally or systemically. The antioncogenic effects are accompanied by an accumulation of miR-34a in the tumor tissue and downregulation of direct miR-34a targets. Intravenous delivery of formulated miR-34a does not induce an elevation of cytokines or liver and kidney enzymes in serum, suggesting that the formulation is well tolerated and does not induce an immune response. The data provide proof of concept for the systemic delivery of a synthetic tumor suppressor mimic, obviating obstacles associated with viral-based miRNA delivery and facilitating a rapid route for miRNA replacement therapy into the clinic. Cancer Res; 70(14); 5923–30. ©2010 AACR.</jats:p>
収録刊行物
-
- Cancer Research
-
Cancer Research 70 (14), 5923-5930, 2010-07-14
American Association for Cancer Research (AACR)
